CDK4 and CDK6 kinases: From basic science to cancer therapy

A Fassl, Y Geng, P Sicinski - Science, 2022 - science.org
BACKGROUND Cyclins and cyclin-dependent kinases (CDKs) drive cell division. Of
particular importance to the cancer field are D-cyclins, which activate CDK4 and CDK6. In …

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

K Pandey, HJ An, SK Kim, SA Lee… - … journal of cancer, 2019 - Wiley Online Library
Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell
proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 …

The DREAM complex functions as conserved master regulator of somatic DNA-repair capacities

A Bujarrabal-Dueso, G Sendtner, DH Meyer… - Nature structural & …, 2023 - nature.com
The DNA-repair capacity in somatic cells is limited compared with that in germ cells. It has
remained unknown whether not only lesion-type-specific, but overall repair capacities could …

Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression

S Ruijtenberg, S van den Heuvel - Cell cycle, 2016 - Taylor & Francis
Cell proliferation and differentiation show a remarkable inverse relationship. Precursor cells
continue division before acquiring a fully differentiated state, while terminal differentiation …

Cell-cycle regulation accounts for variability in Ki-67 expression levels

M Sobecki, K Mrouj, J Colinge, F Gerbe, P Jay… - Cancer research, 2017 - AACR
The cell proliferation antigen Ki-67 is widely used in cancer histopathology, but estimations
of Ki-67 expression levels are inconsistent and understanding of its regulation is limited …

Concept of hybrid drugs and recent advancements in anticancer hybrids

AK Singh, A Kumar, H Singh, P Sonawane, H Paliwal… - Pharmaceuticals, 2022 - mdpi.com
Cancer is a complex disease, and its treatment is a big challenge, with variable efficacy of
conventional anticancer drugs. A two-drug cocktail hybrid approach is a potential strategy in …

Cyclin D-Cdk4, 6 drives cell-cycle progression via the retinoblastoma protein's C-terminal helix

BR Topacio, E Zatulovskiy, S Cristea, S Xie, CS Tambo… - Molecular cell, 2019 - cell.com
The cyclin-dependent kinases Cdk4 and Cdk6 form complexes with D-type cyclins to drive
cell proliferation. A well-known target of cyclin D-Cdk4, 6 is the retinoblastoma protein Rb …

Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry

S Ke, F Dang, L Wang, JY Chen, MT Naik, W Li… - Nature …, 2024 - nature.com
Induced oncoproteins degradation provides an attractive anti-cancer modality. Activation of
anaphase-promoting complex (APC/CCDH1) prevents cell-cycle entry by targeting crucial …

[HTML][HTML] Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic …

MC Papadimitriou, A Pazaiti, K Iliakopoulos… - … et Biophysica Acta (BBA …, 2022 - Elsevier
Abstract Selective CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, have
been approved in combination with hormone therapy for the treatment of patients with HR+ …

CDK4/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions

R Roncato, J Angelini, A Pani, E Cecchin… - International journal of …, 2020 - mdpi.com
Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent
kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic …